Acumen Pharmaceuticals (ABOS) Scheduled to Post Quarterly Earnings on Tuesday

Acumen Pharmaceuticals (NASDAQ:ABOS) is set to issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.

Acumen Pharmaceuticals (NASDAQ:ABOS) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). During the same quarter in the previous year, the business earned ($0.28) earnings per share. On average, analysts expect Acumen Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Acumen Pharmaceuticals Stock Up 1.7 %

NASDAQ:ABOS traded up $0.05 during mid-day trading on Wednesday, reaching $3.05. The stock had a trading volume of 22,662 shares, compared to its average volume of 327,871. The company has a debt-to-equity ratio of 0.12, a current ratio of 17.37 and a quick ratio of 17.37. The stock has a market cap of $183.24 million, a P/E ratio of -2.68 and a beta of 0.04. The business’s 50 day moving average is $2.56 and its 200 day moving average is $2.80. Acumen Pharmaceuticals has a fifty-two week low of $1.81 and a fifty-two week high of $5.09.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. UBS Group decreased their price objective on shares of Acumen Pharmaceuticals from $14.00 to $6.00 and set a “buy” rating for the company in a report on Thursday, August 15th. Citigroup upgraded Acumen Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Acumen Pharmaceuticals in a research note on Thursday, October 3rd.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.